Immunoassay and ELISA Technique Training for Biomedical Scientists

Immunoassays sit at the heart of modern clinical pathology. From thyroid function and cardiac troponin to infectious-disease serology and autoantibody panels, much of what a biomedical scientist (BMS) reports each day depends on an antibody recognising its target with exquisite specificity. That specificity is also the weakness: when something other than the analyte binds the assay antibodies, the result can be badly wrong while looking perfectly normal. This guide explains the core immunoassay formats, how the enzyme-linked immunosorbent assay (ELISA) and automated chemiluminescent platforms generate a signal, how calibration converts that signal into a concentration, and — most importantly for patient safety — how to recognise and mitigate the interferences that catch laboratories out. It is written for NHS trainees and registered scientists across Bands 2 to 8.

How an Immunoassay Works

An immunoassay measures an analyte by exploiting the highly specific binding between an antibody and its antigen (the analyte, or a region of it called an epitope). To turn that binding event into a measurable number, the assay attaches a label — historically an enzyme, now more often a chemiluminescent molecule — to one of the binding partners. The amount of label captured at the end of the reaction is detected as colour, light or current, and that signal is related to the analyte concentration through a calibration curve.

Every immunoassay therefore needs three things: a specific antibody (the reagent), a solid phase to separate bound from unbound material (a microplate well, or a magnetic microparticle in automated systems), and a detection system (the label and a means of reading it). The way these elements are arranged defines the assay format, and the format determines how the assay behaves when something goes wrong.

Immunoassay Formats: Sandwich, Competitive and Indirect

There are three formats every BMS must be able to describe and distinguish, because they fail in opposite directions.

Sandwich (two-site immunometric) assays capture the analyte between two antibodies that bind different epitopes: a plate- or particle-bound capture antibody and a labelled detection antibody. The analyte is "sandwiched" between them, and the signal is directly proportional to analyte concentration. Sandwich formats are sensitive, specific and the most widely used arrangement for larger molecules such as TSH (thyroid-stimulating hormone), troponin and most protein hormones. They require the analyte to carry at least two distinct epitopes, so they are unsuitable for very small molecules.

Competitive (inhibition) assays are used for small molecules with a single epitope, such as steroid hormones, vitamin D and many drugs. Here a fixed, limited amount of antibody is offered both the patient's analyte and a labelled version of the analyte, which compete for the binding sites. The more analyte in the sample, the less labelled material binds, so the signal is inversely proportional to concentration — high analyte gives a low signal.

Indirect assays detect antibodies rather than antigens, and are the workhorse of serology and autoimmunity. The target antigen is fixed to the solid phase, the patient's antibody binds it, and an enzyme-conjugated anti-human secondary antibody is added to generate signal. Because each captured antibody can bind several secondary conjugates, the format amplifies the signal. A direct ELISA is the simplest variant, using a single labelled primary antibody with no secondary step.

Format Detects Signal vs analyte Typical NHS use Key vulnerability
Sandwich (immunometric) Larger antigens (≥2 epitopes) Directly proportional TSH, troponin, hCG, ferritin Hook effect; heterophile bridging
Competitive Small molecules (1 epitope) Inversely proportional Cortisol, vitamin D, oestradiol Inverse bias from interferents
Indirect Antibodies in patient sample Directly proportional Infectious serology, autoantibodies Cross-reactivity; non-specific binding
Direct Antigen with labelled primary Ab Directly proportional Confirmatory / research steps Lower sensitivity, no amplification

ELISA in Practice: A Worked Sandwich Procedure

Although NHS routine work is now dominated by automated analysers, the manual ELISA remains a teaching cornerstone and is still used for some specialist autoimmunity and allergy assays. Understanding the wet-bench steps makes the automated equivalent far easier to troubleshoot. A typical two-step sandwich ELISA runs as follows.

  1. Coat the microplate wells with capture antibody and incubate so it adsorbs to the plastic.
  2. Block the remaining surface with an inert protein (for example bovine serum albumin) to stop later reagents sticking non-specifically.
  3. Add sample and calibrators, incubate, then wash thoroughly to remove unbound material. Washing is the single most common source of poor ELISA performance.
  4. Add the labelled detection antibody, incubate, then wash again.
  5. Add substrate (for an enzyme label such as horseradish peroxidase, a chromogen like TMB), allowing colour to develop in proportion to bound enzyme.
  6. Stop the reaction and read the optical density on a plate reader at the specified wavelength.
  7. Reduce the data by fitting the calibrator signals to a curve and reading patient concentrations from it.

The deliberate wash steps in this two-step design are not just housekeeping — as we will see, they are also the main defence against the high-dose hook effect.

Automated Chemiluminescent Platforms

Most high-throughput NHS immunoassay testing now runs on automated chemiluminescent immunoassay (CLIA) or electrochemiluminescent immunoassay (ECLIA) analysers rather than enzyme/colour ELISA. The underlying immunology is identical — sandwich or competitive binding on a solid phase — but the label and solid phase change.

These platforms offer wide dynamic ranges, low backgrounds and excellent sensitivity, with random-access loading and continuous calibration tracking. Many use a biotin–streptavidin linkage to anchor reagents to the particles — a clever, high-affinity system that, as discussed below, also creates a specific vulnerability to dietary biotin.

Calibration and Traceability

A raw signal means nothing until it is converted to a concentration. Immunoassay calibration uses a set of calibrators of known concentration, run to generate a calibration curve. Because antibody binding saturates at the extremes, the relationship is rarely a straight line; it is sigmoidal, and is most commonly modelled with a four-parameter logistic (4PL) function (a five-parameter logistic, 5PL, is used where the curve is asymmetric). The analyser fits the curve, then interpolates each patient signal to read off a concentration.

Practical points the BMS must own:

Recognising and Mitigating Interferences

Interferences are the reason immunoassay results must always be read against the clinical picture. The three that every immunology and biochemistry BMS should be able to discuss in detail are the high-dose hook effect, heterophile/human anti-animal antibodies, and biotin interference.

The High-Dose Hook Effect

In a sandwich assay, the signal normally rises with analyte. But at extremely high analyte concentrations the capture antibody and the labelled detection antibody can each become saturated separately, so the intact analyte-bridged sandwich fails to form. The signal, having risen, then falls — "hooks" downward — and the analyser reports a falsely low (sometimes normal-looking) result for a grossly elevated analyte. Classic clinical traps include very high hCG in molar pregnancy or germ-cell tumours, prolactin in macroprolactinomas, and high ferritin.

The hook effect is predominantly a problem of one-step assays, where sample and detection antibody are incubated together. Mitigations:

Heterophile and Human Anti-Animal Antibodies

Heterophile antibodies are endogenous human antibodies with broad, weak reactivity against animal immunoglobulins; the more specific human anti-animal antibodies (HAAA) — most famously human anti-mouse antibodies (HAMA), but also anti-goat, anti-sheep and anti-rabbit — arise after exposure to animal proteins, mouse-derived therapeutics or imaging agents. In a sandwich assay these antibodies can bridge the capture and detection antibodies directly, mimicking a real sandwich and producing a false positive (and occasionally a false negative). In a competitive assay they may bind the assay antibody and distort the result.

Detection and mitigation:

Biotin Interference

Many automated platforms use the very strong biotin–streptavidin bond to immobilise reagents. When a patient takes high-dose biotin (vitamin B7, common in over-the-counter hair, skin and nail supplements, and prescribed at high doses in some metabolic and neurological conditions), the free biotin in the sample competes with the assay's biotinylated reagents for the streptavidin solid phase. The direction of error depends on format:

Susceptible tests include troponin, TSH and other thyroid markers, and hCG. The risk is not theoretical: the US Food and Drug Administration has reported a patient death linked to a falsely low troponin caused by biotin interference. Mitigations:

Interference Affected format Direction of error How it is detected Mitigation
High-dose hook Sandwich Falsely low Result rises on dilution; non-linear flag Two-step assay, dilution, clinical correlation
Heterophile / HAAA (HAMA) Mainly sandwich False positive (sometimes negative) Non-linear dilution; blocking shift; alt platform Blocking reagents, antibody fragments, non-mammalian Abs
Biotin Sandwich and competitive Low (sandwich) / high (competitive) Supplement history; retest after washout Washout, depletion, biotin-tolerant assay

Quality, Verification and EQA in the NHS

No immunoassay should report patient results until the laboratory has verified its performance in its own hands. Under ISO 15189:2022, a laboratory introducing a manufacturer-validated assay must verify key performance characteristics — typically imprecision, trueness/bias against the IFU claims, the reportable (measuring) range, and a check on carryover and interferences relevant to the test — and record that the method is fit for its intended clinical use before go-live. Where an assay is modified or has no manufacturer claim, fuller validation is required.

Day to day, performance is held in check by IQC at clinically meaningful concentrations and by participation in external quality assessment. In immunology, UK NEQAS for Immunology, Immunochemistry & Allergy (IIA) — a UKAS-accredited proficiency-testing provider based at the Northern General Hospital in Sheffield and running EQA since 1982 — distributes samples across autoimmunity, immunochemistry, allergy and related schemes, letting laboratories benchmark against peers and catch method-specific bias. EQA performance is also part of the evidence UKAS reviews at assessment.

Frequently Asked Questions

What is the difference between a sandwich and a competitive immunoassay?

A sandwich assay captures the analyte between two antibodies, so the signal rises as concentration rises; it suits larger molecules with at least two epitopes. A competitive assay has the analyte compete with a labelled version for limited antibody, so the signal falls as concentration rises; it suits small single-epitope molecules. Knowing the format tells you which way an interference will push the result.

Why does the high-dose hook effect cause a low result for a high analyte?

At very high analyte levels the capture and detection antibodies become saturated separately, so the bridged sandwich does not form properly and the signal falls instead of continuing to rise. The analyser then reports a falsely low or even normal value despite a grossly elevated analyte. Re-assaying the sample at dilution exposes the effect, because the result rises rather than falls.

How would I confirm heterophile antibody interference at the bench?

Run the sample on serial dilution and look for non-linearity or loss of parallelism, treat the sample with a heterophile blocking reagent and look for a significant shift (commonly over about 20%), and re-test on an alternative platform that uses different antibodies. Agreement between these approaches, alongside a result that does not fit the clinical picture, supports interference. None is perfectly sensitive, so judgement and clinical liaison matter.

Which patients are at risk of biotin interference, and what should I do?

Patients taking high-dose biotin supplements for hair, skin or nails, or prescribed biotin for certain metabolic or neurological conditions, are most at risk. Where a result does not fit, ask about supplements, document the enquiry, and consider retesting after a washout period off biotin or using a biotin-tolerant assay. Be especially alert with troponin, TSH and hCG, which are known to be susceptible.

Why are immunoassay calibration curves not straight lines?

Antibody binding saturates at very low and very high concentrations, so the dose-response relationship is sigmoidal rather than linear. Laboratories therefore model it with a four-parameter logistic (4PL) or five-parameter logistic (5PL) function and interpolate patient signals from the fitted curve. Results above the top calibrator must be diluted and re-run, never extrapolated.

What does ISO 15189:2022 expect before an immunoassay goes live?

For a manufacturer-validated, CE/UKCA-marked assay used as intended, the laboratory must verify that it can reproduce the key performance claims — imprecision, trueness, reportable range and relevant interference/carryover behaviour — and record that the method is suitable for its clinical use. Modified or in-house assays need fuller validation. Ongoing IQC and EQA participation then demonstrate continued fitness for purpose.

Further training

Advance Your Career with PathologyLabTraining

Building strong, current technical skills is what sets confident biomedical scientists apart — in the laboratory, in IBMS portfolio assessment, and at interview. Practising with virtual laboratory simulations, result interpretation exercises, and structured competency scenarios helps you turn the knowledge in this guide into demonstrable, assessable practice across NHS Bands 2-8.

With PathologyLabTraining Premium Access, you get:

Strengthen your laboratory practice with professional-grade training tools. Get started with PathologyLabTraining Premium Access today.

PathologyLabTraining

Your Partner in Professional Success

Email us at: [email protected]

Follow us on social media:

Stay updated with the latest interview tips, resources, and biomedical science insights!

Quick Links:

© 2026 PathologyLabTraining.co.uk. All Rights Reserved.